These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 19494791)

  • 1. NAD(P)H:quinone oxidoreductase 1 Pro187Ser polymorphism and expression do not cosegregate with clinico-pathological characteristics of human mammary tumors.
    Hubackova M; Vaclavikova R; Mrhalova M; Kubackova K; Kodet R; Gut I; Soucek P
    Pharmacogenet Genomics; 2009 Jul; 19(7):505-12. PubMed ID: 19494791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased levels of NAD(P)H: quinone oxidoreductase 1 (NQO1) in pancreatic tissues from smokers and pancreatic adenocarcinomas: A potential biomarker of early damage in the pancreas.
    Lyn-Cook BD; Yan-Sanders Y; Moore S; Taylor S; Word B; Hammons GJ
    Cell Biol Toxicol; 2006 Mar; 22(2):73-80. PubMed ID: 16532285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism.
    Jamieson D; Wilson K; Pridgeon S; Margetts JP; Edmondson RJ; Leung HY; Knox R; Boddy AV
    Clin Cancer Res; 2007 Mar; 13(5):1584-90. PubMed ID: 17332305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence on the association between NQO1 Pro187Ser polymorphism and breast cancer risk in the current studies: a meta-analysis.
    Yuan W; Xu L; Chen W; Wang L; Fu Z; Pang D; Li D
    Breast Cancer Res Treat; 2011 Jan; 125(2):467-72. PubMed ID: 20526805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer.
    Fagerholm R; Hofstetter B; Tommiska J; Aaltonen K; Vrtel R; Syrjäkoski K; Kallioniemi A; Kilpivaara O; Mannermaa A; Kosma VM; Uusitupa M; Eskelinen M; Kataja V; Aittomäki K; von Smitten K; Heikkilä P; Lukas J; Holli K; Bartkova J; Blomqvist C; Bartek J; Nevanlinna H
    Nat Genet; 2008 Jul; 40(7):844-53. PubMed ID: 18511948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association analysis of NAD(P)H:quinone oxidoreductase gene 609 C/T polymorphism with Alzheimer's disease.
    Wang B; Jin F; Xie Y; Tang Y; Kan R; Zheng C; Yang Z; Wang L
    Neurosci Lett; 2006 Dec; 409(3):179-81. PubMed ID: 17027152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity.
    Traver RD; Horikoshi T; Danenberg KD; Stadlbauer TH; Danenberg PV; Ross D; Gibson NW
    Cancer Res; 1992 Feb; 52(4):797-802. PubMed ID: 1737339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes.
    Zai CC; Tiwari AK; Basile V; de Luca V; Müller DJ; Voineskos AN; Remington G; Meltzer HY; Lieberman JA; Potkin SG; Kennedy JL
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):50-6. PubMed ID: 19778569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NAD(P)H:Quinone oxidoreductase-1 C609T polymorphism analysis in human superficial bladder cancers: relationship of genotype status to NQO1 phenotype and clinical response to Mitomycin C.
    Basu S; Brown JE; Flannigan GM; Gill JH; Loadman PM; Martin SW; Naylor B; Puri R; Scally AJ; Seargent JM; Shah T; Phillips RM
    Int J Oncol; 2004 Oct; 25(4):921-7. PubMed ID: 15375541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis.
    Chao C; Zhang ZF; Berthiller J; Boffetta P; Hashibe M
    Cancer Epidemiol Biomarkers Prev; 2006 May; 15(5):979-87. PubMed ID: 16702380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NQO1 expression correlates inversely with NFκB activation in human breast cancer.
    Jamshidi M; Bartkova J; Greco D; Tommiska J; Fagerholm R; Aittomäki K; Mattson J; Villman K; Vrtel R; Lukas J; Heikkilä P; Blomqvist C; Bartek J; Nevanlinna H
    Breast Cancer Res Treat; 2012 Apr; 132(3):955-68. PubMed ID: 21706157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of bladder cancer risk with an NAD(P)H:quinone oxidoreductase polymorphism in an ethnic Kashmiri population.
    Pandith AA; Khan NP; Shah ZA; Shah AM; Wani SM; Siddiqi MA
    Biochem Genet; 2011 Aug; 49(7-8):417-26. PubMed ID: 21253823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of NAD(P)H:quinone oxidoreductase 1 (NQO1) C609T polymorphism in prostate cancer.
    Ergen HA; Gormus U; Narter F; Zeybek U; Bulgurcuoglu S; Isbir T
    Anticancer Res; 2007; 27(6B):4107-10. PubMed ID: 18225579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The NQO1 Pro187Ser polymorphism and breast cancer susceptibility: evidence from an updated meta-analysis.
    Peng Q; Lu Y; Lao X; Chen Z; Li R; Sui J; Qin X; Li S
    Diagn Pathol; 2014 May; 9():100. PubMed ID: 24884893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral contraceptive use and breast cancer risk: modification by NAD(P)H:quinone oxoreductase (NQO1) genetic polymorphisms.
    Fowke JH; Shu XO; Dai Q; Jin F; Cai Q; Gao YT; Zheng W
    Cancer Epidemiol Biomarkers Prev; 2004 Aug; 13(8):1308-15. PubMed ID: 15298951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of superoxide dismutases and NAD(P)H quinone oxidoreductases with prognosis of patients with breast carcinomas.
    Hubackova M; Vaclavikova R; Ehrlichova M; Mrhalova M; Kodet R; Kubackova K; Vrána D; Gut I; Soucek P
    Int J Cancer; 2012 Jan; 130(2):338-48. PubMed ID: 21351093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between polymorphisms in apoptotic genes and susceptibility for developing breast cancer in Syrian women.
    Lajin B; Alhaj Sakur A; Alachkar A
    Breast Cancer Res Treat; 2013 Apr; 138(2):611-9. PubMed ID: 23468244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The frequencies of NAD(P)H quinone oxidoreductase (NQO1) variant allele in Israeli ethnic groups and the relationship of NQO1*2 to adult acute myeloid leukemia in Israeli patients.
    Malik E; Cohen SB; Sahar D; Dann EJ; Rund D
    Haematologica; 2006 Jul; 91(7):956-9. PubMed ID: 16818284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association analyses between polymorphisms of the phase II detoxification enzymes (GSTM1, NQO1, NQO2) and alcohol withdrawal symptoms.
    Okubo T; Harada S; Higuchi S; Matsushita S
    Alcohol Clin Exp Res; 2003 Aug; 27(8 Suppl):68S-71S. PubMed ID: 12960511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An association between a NQO1 genetic polymorphism and risk of lung cancer.
    Saldivar SJ; Wang Y; Zhao H; Shao L; Lin J; Spitz MR; Wu X
    Mutat Res; 2005 Apr; 582(1-2):71-8. PubMed ID: 15781212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.